Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants: a randomized controlled trial
J Tan, W Wu, X Xu, L Liao, F Zheng, S Messinger… - Jama, 2012 - jamanetwork.com
Context Antibody-based induction therapy plus calcineurin inhibitors (CNIs) reduce acute
rejection rates in kidney recipients; however, opportunistic infections and toxic CNI effects
remain challenging. Reportedly, mesenchymal stem cells (MSCs) have successfully treated
graft-vs-host disease. Objective To assess autologous MSCs as replacement of antibody
induction for patients with end-stage renal disease who undergo ABO-compatible, cross-
match–negative kidney transplants from a living-related donor. Design, Setting, and Patients …
rejection rates in kidney recipients; however, opportunistic infections and toxic CNI effects
remain challenging. Reportedly, mesenchymal stem cells (MSCs) have successfully treated
graft-vs-host disease. Objective To assess autologous MSCs as replacement of antibody
induction for patients with end-stage renal disease who undergo ABO-compatible, cross-
match–negative kidney transplants from a living-related donor. Design, Setting, and Patients …
